For 25 years now, BioM has been the network organisation of the biotechnology sector in Munich and Bavaria. To shape the future of biotechnology, BioM identifies relevant and sustainable local, regional and global trends and creates a unique ecosystem for innovation and growth.
French pharma major Sanofi SA will pay US$175m upfront to Janssen Pharmaceuticals, Inc. for commercialisation of a Phase III vaccine against extraintestinal pathogenic E. coli.
The Spanish EU Council Presidency is to set the course for the internationally competitive use of biotechnology in drug development, plant breeding and food production.
After two years of unprecedented growth driven by the pandemic, investment attracted by Spanish biotech companies has stabilised, and they face significant challenges, positioning biotechnology as a strategic sector for Spain.
British in-vivo cell programming specialist Mogrify Ltd has added US$10m to its US$36m Series A financing.